Small molecule · developed by Soligenix
SGX201 is delayed-release beclomethasone 17,21-dipropionate, a corticosteroid formulation. It is being studied in enteritis, with dosing given before the first radiation therapy session and continuing for 7 days after radiation therapy ends.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01073384 | Phase 1/2 | Enteritis | Completed | SNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Enteritis
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNGX page.
See SNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNGX catalysts and pipeline →